These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 23505124)

  • 1. Intramuscular aripiprazole in the acute management of psychomotor agitation.
    De Filippis S; Cuomo I; Lionetto L; Janiri D; Simmaco M; Caloro M; De Persis S; Piazzi G; Simonetti A; Telesforo CL; Sciarretta A; Caccia F; Gentile G; Kotzalidis GD; Girardi P
    Pharmacotherapy; 2013 Jun; 33(6):603-14. PubMed ID: 23505124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intramuscular aripiprazole in the control of agitation.
    Currier GW; Citrome LL; Zimbroff DL; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
    J Psychiatr Pract; 2007 May; 13(3):159-69. PubMed ID: 17522559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole.
    Zimbroff DL; Marcus RN; Manos G; Stock E; McQuade RD; Auby P; Oren DA
    J Clin Psychopharmacol; 2007 Apr; 27(2):171-6. PubMed ID: 17414241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
    Daniel DG; Currier GW; Zimbroff DL; Allen MH; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
    J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study.
    Andrezina R; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; McQuade RD
    Curr Med Res Opin; 2006 Nov; 22(11):2209-19. PubMed ID: 17076982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.
    Tran-Johnson TK; Sack DA; Marcus RN; Auby P; McQuade RD; Oren DA
    J Clin Psychiatry; 2007 Jan; 68(1):111-9. PubMed ID: 17284138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
    Andrezina R; Josiassen RC; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; Iwamoto T
    Psychopharmacology (Berl); 2006 Oct; 188(3):281-92. PubMed ID: 16953381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia.
    Rappaport SA; Marcus RN; Manos G; McQuade RD; Oren DA
    J Am Med Dir Assoc; 2009 Jan; 10(1):21-7. PubMed ID: 19111849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.
    Huang CL; Hwang TJ; Chen YH; Huang GH; Hsieh MH; Chen HH; Hwu HG
    J Formos Med Assoc; 2015 May; 114(5):438-45. PubMed ID: 25791540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
    Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
    J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial.
    Kittipeerachon M; Chaichan W
    Schizophr Res; 2016 Oct; 176(2-3):231-238. PubMed ID: 27461399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.
    San L; Estrada G; Oudovenko N; Vieta E
    BMC Psychiatry; 2017 Apr; 17(1):126. PubMed ID: 28376877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
    Robb AS; Carson WH; Nyilas M; Ali M; Forbes RA; Iwamoto T; Assunção-Talbott S; Whitehead R; Pikalov A
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):33-8. PubMed ID: 20166794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
    Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
    J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?].
    Charpeaud T; Samalin L; Llorca PM
    Encephale; 2014 Feb; 40(1):62-73. PubMed ID: 24445245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
    J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Allen MH; Feifel D; Lesem MD; Zimbroff DL; Ross R; Munzar P; Spyker DA; Cassella JV
    J Clin Psychiatry; 2011 Oct; 72(10):1313-21. PubMed ID: 21294997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.